A Max-Ad Vaccine for Mucosal Immunity to HIV
A Max-Ad Vaccine for Mucosal Immunity to HIV
批准号:
6511633
负责人:
Sybille L Sauter
金额:
$20.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-30 至 2003-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by Applicant): To date there is no effective HIV vaccine
available. Development of a beneficial HIV vaccine has been challenging due to
the high mutation rate of the virus, in particular the envelope protein. Many
of the 25 or more different HIV vaccines now in clinical trials target the
envelope protein in an effort to raise an antibody response to that protein.
New insight into effective anti-viral vaccines has focused attention on
eliciting cellular immune responses. In addition, mucosal immunity to HIV is
desirable for an effective HIV vaccine, since mucosal tissues are the common
sites of initial infection.
The vaccine being developed by GenStar targets these two issues by the
inclusion of the HIV components known to elicit the best cellular immune
responses and the ability of adenovirus to produce excellent mucosal immunity.
GenStar's proprietary adenoviral vector, Max-Ad, is particularly suited for
this approach, since it is a gutless adenovirus with a very large insert
capacity. This capacity not only allows the inclusion of multiple HIV
components but also the gene for the immunostimulatory cytokine, GM-CSF. In
addition, this virus offers efficient transduction of most cells including
dendritic cells, excellent high titer large-scale production, and the lack of
synthesis of any adenoviral proteins. In the proposed studies we intend to
determine the ability of a Max-Ad/HIV vaccine to elicit cellular immune
responses to HIV through mucosal delivery.
PROPOSED COMMERCIAL APPLICATION:
HIV is a world-wide health problem with over 30 million people infected and 15,000 new cases of HIV infections diagnosed each day. Clearly, a prophylactic vaccine for this infectious disease is urgently needed and would produce significant financial and social returns. The potential for effective immunization via a mucosal route such as intranasal spray is particularly attractive in view of the large population at risk and the ease of administration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Non-Integrating FIV Vectors for HIV Vaccines
-
批准号:7123310
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2006
-
负责人:Sybille L Sauter
-
依托单位:
FIV Vectors for the Treatment of Hemophilia A
-
批准号:6992338
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2005
-
负责人:Sybille L Sauter
-
依托单位:
A Lentivirus Vaccine for HIV
-
批准号:6746111
-
项目类别:
-
资助金额:$27.15万
-
财政年份:2004
-
负责人:Sybille L Sauter
-
依托单位:
Lentiviral Vector Gene Therapy for CD45 Deliver
-
批准号:6645847
-
项目类别:
-
资助金额:$37.44万
-
财政年份:2003
-
负责人:Sybille L Sauter
-
依托单位:
Lentiviral Vector Gene Therapy for CD45 Deliver
-
批准号:6751633
-
项目类别:
-
资助金额:$37.44万
-
财政年份:2003
-
负责人:Sybille L Sauter
-
依托单位:
Non-Primate FIV Vectors for Treatment of Hemophilia A
-
批准号:6444339
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:Sybille L Sauter
-
依托单位:
A Lentivirus Vaccine for HIV
-
批准号:6409274
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2001
-
负责人:Sybille L Sauter
-
依托单位:
A Max-Ad Vaccine for Mucosal Immunity to HIV
-
批准号:6402992
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2001
-
负责人:Sybille L Sauter
-
依托单位:
A Lentivirus Vaccine for HIV
-
批准号:6534363
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2001
-
负责人:Sybille L Sauter
-
依托单位:
海外基金